Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
71 hedge funds and large institutions have $750M invested in Kinnate Biopharma Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 12 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 14
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
3% less funds holding
Funds holding: 73 → 71 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
17% less capital invested
Capital invested by funds: $905M → $750M (-$155M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Natixis
Paris,
France
|
+$14.2M |
| 2 |
BlackRock
New York
|
+$3.64M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.28M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.19M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$14.8M |
| 2 |
Morgan Stanley
New York
|
-$7.75M |
| 3 |
Millennium Management
New York
|
-$2.73M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.17M |
| 5 |
DM
Deerfield Management
New York
|
-$906K |
KNTE Hedge Fund Activity: Q4 2021 in Review
71 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q4 2021, worth a combined $750M — down 17% from $905M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of KNTE and 10 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 25 added.
The largest buyer was Natixis, opening a new position worth an estimated $14.2M. The largest seller was VR Adviser, cutting an estimated $14.8M.
- 71 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q4 2021, down from 73 in Q3 2021.
- Funds reported $750M of Kinnate Biopharma Inc. Common Stock stock for Q4 2021, down 17% quarter-over-quarter.
- 10 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q4 2021 and 12 closed out, a net change of -2 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q4 2021 was Natixis, an estimated $14.2M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q4 2021 was VR Adviser, an estimated $14.8M sold.
Based on aggregated 13F filings for Q4 2021.